Bio-Gene Technology（BGT）株式概要バイオ・ジーン・テクノロジー社は農業技術開発会社で、天然由来の殺虫剤製品の開発と商業化をオーストラリア国内外で行っている。 詳細BGT ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析過去1年間で株主の希薄化は大幅に進んだ 意味のある時価総額がありません ( A$7M )収益が 100 万ドル未満 ( A$0 )Australian市場と比較して、過去 3 か月間の株価の変動が非常に大きいすべてのリスクチェックを見るBGT Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW502,015 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG502,015 investors already sharing narrativesYour Fair ValueAU$Current PriceAU$0.018該当なし内在価値ディスカウントEst. Revenue$PastFuture-3m507k2016201920222025202620282031Revenue AU$0.09Earnings AU$0.008AdvancedSet Fair ValueView all narrativesBio-Gene Technology Limited 競合他社DanakaliSymbol: NSX:DNKMarket cap: AU$15.6mTerragen HoldingsSymbol: ASX:TGHMarket cap: AU$15.6mHighfield ResourcesSymbol: ASX:HFRMarket cap: AU$9.0mNeuRizerSymbol: ASX:NRZMarket cap: AU$3.4m価格と性能株価の高値、安値、推移の概要Bio-Gene Technology過去の株価現在の株価AU$0.01852週高値AU$0.0652週安値AU$0.016ベータ0.761ヶ月の変化-18.18%3ヶ月変化-45.45%1年変化-10.00%3年間の変化-79.55%5年間の変化-89.41%IPOからの変化-92.17%最新ニュースNew Risk • Jun 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 45% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (45% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$7.72m market cap, or US$5.33m).お知らせ • May 26+ 1 more updateBio-Gene Technology Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.Bio-Gene Technology Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 60,000,000 Price\Range: AUD 0.025 Security Features: Attached OptionsBoard Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. MD, CEO & Director Tim Grogan was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 30Bio-Gene Technology Limited, Annual General Meeting, Nov 19, 2025Bio-Gene Technology Limited, Annual General Meeting, Nov 19, 2025.お知らせ • May 05+ 1 more updateBio-Gene Technology Limited has filed a Follow-on Equity Offering in the amount of AUD 0.69 million.Bio-Gene Technology Limited has filed a Follow-on Equity Offering in the amount of AUD 0.69 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 30,000,000 Price\Range: AUD 0.023 Security Features: Attached OptionsBoard Change • Feb 04No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.最新情報をもっと見るRecent updatesNew Risk • Jun 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 45% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (45% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$7.72m market cap, or US$5.33m).お知らせ • May 26+ 1 more updateBio-Gene Technology Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.Bio-Gene Technology Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 60,000,000 Price\Range: AUD 0.025 Security Features: Attached OptionsBoard Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. MD, CEO & Director Tim Grogan was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 30Bio-Gene Technology Limited, Annual General Meeting, Nov 19, 2025Bio-Gene Technology Limited, Annual General Meeting, Nov 19, 2025.お知らせ • May 05+ 1 more updateBio-Gene Technology Limited has filed a Follow-on Equity Offering in the amount of AUD 0.69 million.Bio-Gene Technology Limited has filed a Follow-on Equity Offering in the amount of AUD 0.69 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 30,000,000 Price\Range: AUD 0.023 Security Features: Attached OptionsBoard Change • Feb 04No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Oct 04Bio-Gene Technology Limited, Annual General Meeting, Nov 29, 2024Bio-Gene Technology Limited, Annual General Meeting, Nov 29, 2024.Board Change • Oct 02No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.New Risk • Aug 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$2.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.8m free cash flow). Shares are highly illiquid. Earnings have declined by 9.0% per year over the past 5 years. Revenue is less than US$1m (AU$710k revenue, or US$483k). Market cap is less than US$10m (AU$9.26m market cap, or US$6.30m). Minor Risk Shareholders have been diluted in the past year (13% increase in shares outstanding).Board Change • Jun 21No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 5 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • May 21No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 5 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.New Risk • Feb 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 7.4% per year over the past 5 years. Revenue is less than US$1m (AU$149k revenue, or US$97k). Market cap is less than US$10m (AU$11.1m market cap, or US$7.22m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (13% increase in shares outstanding).Board Change • Feb 14No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Nov 29No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Nov 23Bio-Gene Technology Limited Approves the Election of Alex Ding as DirectorBio-Gene Technology Limited at its AGM held on November 23, 2023, approved the election of Mr. Alex Ding as a Director.お知らせ • Nov 15+ 1 more updateBio-Gene Technology Limited Announces Resignation of Rodrigo Valencia as Joint CFOBio-Gene Technology Limited announced the resignation of Mr. Rodrigo Valencia as joint CFO and Company Secretary effective immediately. Mr. Roger McPherson will remain with Bio-Gene, on an interim basis, as the sole CFO and Company Secretary, while the Company seeks a suitable permanent replacement.お知らせ • Oct 30Bio-Gene Technology Limited Announces the Appointment of Roger Mcpherson as Joint Company SecretaryBio-Gene Technology Limited announced the appointment of Mr. Roger McPherson as joint Company Secretary on an interim basis. Roger has more than 25 years' experience in senior finance roles in a wide variety of industries. His early career included working with a Chartered Accounting practice and two years with the Australian Taxation Office. In the past, Roger was CFO and Company Secretary for a number of SMEs both listed and unlisted including Bio- Gene, Patrys Limited, TPI Enterprises Ltd. and eChoice Home Loans. In these roles he was responsible for all financial affairs and corporate administration as well as assisting in investor relations activities. He has over 20 years of biotechnology and pharmaceutical experience. In addition to his role with Bio-Gene, Roger also provides CFO services to other unlisted entities.Board Change • Oct 30No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Oct 02Bio-Gene Technology Limited, Annual General Meeting, Nov 23, 2023Bio-Gene Technology Limited, Annual General Meeting, Nov 23, 2023, at 11:01 AUS Eastern Standard Time.New Risk • Sep 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.3m free cash flow). Shares are highly illiquid. Earnings have declined by 7.4% per year over the past 5 years. Revenue is less than US$1m (AU$149k revenue, or US$95k). Minor Risks Shareholders have been diluted in the past year (5.4% increase in shares outstanding). Market cap is less than US$100m (AU$17.6m market cap, or US$11.2m).Board Change • Sep 05No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.New Risk • Aug 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$3.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.3m free cash flow). Shares are highly illiquid. Earnings have declined by 7.4% per year over the past 5 years. Revenue is less than US$1m (AU$681k revenue, or US$458k). Minor Risk Market cap is less than US$100m (AU$15.1m market cap, or US$10.2m).Reported Earnings • Aug 01Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.019 loss in FY 2022)Full year 2023 results: AU$0.018 loss per share. Net loss: AU$3.10m (loss widened 6.2% from FY 2022).お知らせ • Jul 28+ 1 more updateBio-Gene Technology Limited Announces Managing Director ChangesBio-Gene Technology Limited announced the following executive changes: Mr. Tim Grogan has been appointed Managing Director, effective from 28th August 2023. Mr. Richard Jagger formally resigns as current Managing Director to transition to a new advisory role focused on stakeholder management of Bio-Gene's existing and future development partnerships at the end of September. Tim brings more than 30 years' experience and expertise to Bio-Gene, with a successful track record of delivering growth in the agtech, food and human health sectors. Tim has deep multi-disciplinary experience in the management of new product development, commercialisation, capital raising and corporate governance. As a hands-on leader, Tim has held several key executive roles, specialising in product development and expanding business partnerships. As CEO of SIRA Pty Ltd, Tim led the commercial development of technologies to produce new types of healthier sugar. Prior to this, Tim was the CEO of Dimerix BioScience Pty Ltd, where he managed the development of a novel treatment for diabetic nephropathy and the company completed three substantial pharmaceutical partnering deals within 12 months and significantly expanded its investor base. Tim also has extensive listed company experience, including with pharmaceutical development company, Starpharma, where he worked to steer it through the IPO process and establishing several commercial relationships globally. Most recently, Tim has been consulting to companies in the health and medical technology sectors in Australia, providing strategic, government and regulatory advice. Tim holds a Bachelor of Law and a Bachelor of Science, majoring in chemistry, from the University of Melbourne.Board Change • Jul 10No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 7 non-independent directors. Director Alex Huong was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.New Risk • Jun 23New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.3m (US$9.58m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 4.6% per year over the past 5 years. Revenue is less than US$1m (AU$97k revenue, or US$65k). Market cap is less than US$10m (AU$14.3m market cap, or US$9.58m).Board Change • Jun 22No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 7 non-independent directors. Director Alex Huong was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.お知らせ • May 12Bio-Gene Technology Limited Announces Changes to the BoardBio-Gene Technology Limited announced the following changes to the Board and management: Due to significantly increased commitments associated with his other roles, Mr. Robert Klupacs has advised the Board that he will be retiring from the Board effective 31 July 2023. Before that time he will continue to act as Chair of the Company, and will be heavily involved in strategic negotiations for the company alongside the Bio- Gene management team. Robert joined Bio-Gene in 2015 as CEO and lead the Company to IPO in 2017, before becoming a Non-Executive Director in January 2018. Robert became Chair of the Company in November 2019. The Company also announces that Mr. Alex Ding and Mr. Chris Ramsay will join the Bio-Gene Board, effective immediately. Alex Ding was a partner at two leading Australian law firms, and is a recognised expert in mergers and acquisitions, capital markets, and general corporate and governance law. He has advised many large ASX, LSE and US listed companies, foreign government controlled entities and substantial private companies and funds on acquisitions, divestments, corporate finance transactions, joint venture arrangements, restructurings, corporate governance and disputes strategy. He has been named on The Best Lawyers in Australia list. Christopher Ramsay has over 30 years experience in the agricultural sector across business development, marketing and broader agronomy. He has held leadership roles in BASF and Nufarm among others, operating in both technical and managerial roles. Chris brings with him significant experience across customer engagement and product marketing and has a history of partnership development and sourcing after having spent the earlier years of his career in technical agricultural roles. Chris currently acts as non-executive director of North West Phosphate, a phosphate exploration and production business and principal director of a boutique agribusiness consulting firm. Chris holds a BSc (Honours) in Rural Sciences and a GradDip in Agribusiness.Board Change • Apr 26No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Mar 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 24First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.01 loss in 1H 2022)First half 2023 results: AU$0.012 loss per share (further deteriorated from AU$0.01 loss in 1H 2022). Net loss: AU$1.97m (loss widened 37% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.Board Change • Jan 05No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Dec 10No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 18Full year 2022 earnings released: AU$0.019 loss per share (vs AU$0.017 loss in FY 2021)Full year 2022 results: AU$0.019 loss per share (down from AU$0.017 loss in FY 2021). Net loss: AU$2.91m (loss widened 22% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 1% per year.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 22First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: AU$0.01 loss per share (vs AU$0.01 loss in 1H 2021). Net loss: AU$1.44m (loss widened 8.1% from 1H 2021). Revenue missed analyst estimates by 95%. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 28Full year 2021 earnings released: AU$0.017 loss per share (vs AU$0.016 loss in FY 2020)Full year 2021 results: Net loss: AU$2.40m (loss widened 24% from FY 2020).Breakeven Date Change • Jul 27Forecast to breakeven in 2024The analyst covering Bio-Gene Technology expects the company to break even for the first time. New forecast suggests the company will make a profit of AU$1.50m in 2024. Average annual earnings growth of 78% is required to achieve expected profit on schedule.Breakeven Date Change • Jul 03Forecast to breakeven in 2024The analyst covering Bio-Gene Technology expects the company to break even for the first time. New forecast suggests the company will make a profit of AU$1.50m in 2024. Average annual earnings growth of 78% is required to achieve expected profit on schedule.Reported Earnings • Feb 19First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.009 loss in 1H 2020)First half 2021 results: Net loss: AU$1.33m (loss widened 25% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.株主還元BGTAU ChemicalsAU 市場7D0%-0.9%0.2%1Y-10.0%19.0%1.8%株主還元を見る業界別リターン: BGT過去 1 年間で19 % の収益を上げたAustralian Chemicals業界を下回りました。リターン対市場: BGTは、過去 1 年間で1.8 % のリターンを上げたAustralian市場を下回りました。価格変動Is BGT's price volatile compared to industry and market?BGT volatilityBGT Average Weekly Movement17.7%Chemicals Industry Average Movement10.1%Market Average Movement9.7%10% most volatile stocks in AU Market16.7%10% least volatile stocks in AU Market4.0%安定した株価: BGTの株価は、 Australian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: BGTの weekly volatility ( 18% ) は過去 1 年間安定していますが、依然としてAustralianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1995n/aTim Groganwww.bio-gene.com.auバイオ・ジーン・テクノロジー社は農業技術開発会社で、天然由来の殺虫剤製品の開発と商業化をオーストラリア国内外で行っている。同社の製品には、合成生産された自然界と同一の化合物であるFlavocide、タスマノンを多く含む天然植物由来のオイルであるQcideなどがある。ジェームズ・クック大学とは、バイオマスからの油の加工と蒸留に関する研究と現場作業を支援する研究協力協定を結んでいる。化学製品のAgriFor Scientific、様々な昆虫種に対する分子の殺虫活性を評価するcesar、化学開発プロセスのCSIRO；穀物貯蔵害虫に対する活性を評価するクイーンズランド州政府農業漁業省、ユーロフィンズ、グレイン・リサーチ・デベロップメント・コーポレーション、パシフィック・ディスカバリー・サービス、パデュー大学、天然物の化学分析を行うサザンクロス大学、フロリダ大学、工科大学。動物衛生、農作物保護、穀物貯蔵、公衆衛生、消費者用途にサービスを提供している。同社は1995年に法人化され、オーストラリアのメルボルンを拠点としている。もっと見るBio-Gene Technology Limited 基礎のまとめBio-Gene Technology の収益と売上を時価総額と比較するとどうか。BGT 基礎統計学時価総額AU$6.56m収益（TTM）-AU$2.52m売上高(TTM)n/a0.0xP/Sレシオ-2.6xPER（株価収益率BGT は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計BGT 損益計算書（TTM）収益AU$0売上原価-AU$80.35k売上総利益AU$80.35kその他の費用AU$2.60m収益-AU$2.52m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.0065グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%BGT の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/07 12:31終値2026/07/07 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bio-Gene Technology Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Tom WaitePAC Partners Securities Pty. Ltd.
New Risk • Jun 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 45% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (45% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$7.72m market cap, or US$5.33m).
お知らせ • May 26+ 1 more updateBio-Gene Technology Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.Bio-Gene Technology Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 60,000,000 Price\Range: AUD 0.025 Security Features: Attached Options
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. MD, CEO & Director Tim Grogan was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 30Bio-Gene Technology Limited, Annual General Meeting, Nov 19, 2025Bio-Gene Technology Limited, Annual General Meeting, Nov 19, 2025.
お知らせ • May 05+ 1 more updateBio-Gene Technology Limited has filed a Follow-on Equity Offering in the amount of AUD 0.69 million.Bio-Gene Technology Limited has filed a Follow-on Equity Offering in the amount of AUD 0.69 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 30,000,000 Price\Range: AUD 0.023 Security Features: Attached Options
Board Change • Feb 04No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
New Risk • Jun 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 45% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (45% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$7.72m market cap, or US$5.33m).
お知らせ • May 26+ 1 more updateBio-Gene Technology Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million.Bio-Gene Technology Limited has filed a Follow-on Equity Offering in the amount of AUD 1.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 60,000,000 Price\Range: AUD 0.025 Security Features: Attached Options
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. MD, CEO & Director Tim Grogan was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 30Bio-Gene Technology Limited, Annual General Meeting, Nov 19, 2025Bio-Gene Technology Limited, Annual General Meeting, Nov 19, 2025.
お知らせ • May 05+ 1 more updateBio-Gene Technology Limited has filed a Follow-on Equity Offering in the amount of AUD 0.69 million.Bio-Gene Technology Limited has filed a Follow-on Equity Offering in the amount of AUD 0.69 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 30,000,000 Price\Range: AUD 0.023 Security Features: Attached Options
Board Change • Feb 04No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Oct 04Bio-Gene Technology Limited, Annual General Meeting, Nov 29, 2024Bio-Gene Technology Limited, Annual General Meeting, Nov 29, 2024.
Board Change • Oct 02No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
New Risk • Aug 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$2.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.8m free cash flow). Shares are highly illiquid. Earnings have declined by 9.0% per year over the past 5 years. Revenue is less than US$1m (AU$710k revenue, or US$483k). Market cap is less than US$10m (AU$9.26m market cap, or US$6.30m). Minor Risk Shareholders have been diluted in the past year (13% increase in shares outstanding).
Board Change • Jun 21No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 5 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • May 21No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 5 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
New Risk • Feb 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 7.4% per year over the past 5 years. Revenue is less than US$1m (AU$149k revenue, or US$97k). Market cap is less than US$10m (AU$11.1m market cap, or US$7.22m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (13% increase in shares outstanding).
Board Change • Feb 14No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Nov 29No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Nov 23Bio-Gene Technology Limited Approves the Election of Alex Ding as DirectorBio-Gene Technology Limited at its AGM held on November 23, 2023, approved the election of Mr. Alex Ding as a Director.
お知らせ • Nov 15+ 1 more updateBio-Gene Technology Limited Announces Resignation of Rodrigo Valencia as Joint CFOBio-Gene Technology Limited announced the resignation of Mr. Rodrigo Valencia as joint CFO and Company Secretary effective immediately. Mr. Roger McPherson will remain with Bio-Gene, on an interim basis, as the sole CFO and Company Secretary, while the Company seeks a suitable permanent replacement.
お知らせ • Oct 30Bio-Gene Technology Limited Announces the Appointment of Roger Mcpherson as Joint Company SecretaryBio-Gene Technology Limited announced the appointment of Mr. Roger McPherson as joint Company Secretary on an interim basis. Roger has more than 25 years' experience in senior finance roles in a wide variety of industries. His early career included working with a Chartered Accounting practice and two years with the Australian Taxation Office. In the past, Roger was CFO and Company Secretary for a number of SMEs both listed and unlisted including Bio- Gene, Patrys Limited, TPI Enterprises Ltd. and eChoice Home Loans. In these roles he was responsible for all financial affairs and corporate administration as well as assisting in investor relations activities. He has over 20 years of biotechnology and pharmaceutical experience. In addition to his role with Bio-Gene, Roger also provides CFO services to other unlisted entities.
Board Change • Oct 30No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (6 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Oct 02Bio-Gene Technology Limited, Annual General Meeting, Nov 23, 2023Bio-Gene Technology Limited, Annual General Meeting, Nov 23, 2023, at 11:01 AUS Eastern Standard Time.
New Risk • Sep 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.3m free cash flow). Shares are highly illiquid. Earnings have declined by 7.4% per year over the past 5 years. Revenue is less than US$1m (AU$149k revenue, or US$95k). Minor Risks Shareholders have been diluted in the past year (5.4% increase in shares outstanding). Market cap is less than US$100m (AU$17.6m market cap, or US$11.2m).
Board Change • Sep 05No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 4 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Executive Director of Research & Development and Executive Director Peter May is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
New Risk • Aug 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$3.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.3m free cash flow). Shares are highly illiquid. Earnings have declined by 7.4% per year over the past 5 years. Revenue is less than US$1m (AU$681k revenue, or US$458k). Minor Risk Market cap is less than US$100m (AU$15.1m market cap, or US$10.2m).
Reported Earnings • Aug 01Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.019 loss in FY 2022)Full year 2023 results: AU$0.018 loss per share. Net loss: AU$3.10m (loss widened 6.2% from FY 2022).
お知らせ • Jul 28+ 1 more updateBio-Gene Technology Limited Announces Managing Director ChangesBio-Gene Technology Limited announced the following executive changes: Mr. Tim Grogan has been appointed Managing Director, effective from 28th August 2023. Mr. Richard Jagger formally resigns as current Managing Director to transition to a new advisory role focused on stakeholder management of Bio-Gene's existing and future development partnerships at the end of September. Tim brings more than 30 years' experience and expertise to Bio-Gene, with a successful track record of delivering growth in the agtech, food and human health sectors. Tim has deep multi-disciplinary experience in the management of new product development, commercialisation, capital raising and corporate governance. As a hands-on leader, Tim has held several key executive roles, specialising in product development and expanding business partnerships. As CEO of SIRA Pty Ltd, Tim led the commercial development of technologies to produce new types of healthier sugar. Prior to this, Tim was the CEO of Dimerix BioScience Pty Ltd, where he managed the development of a novel treatment for diabetic nephropathy and the company completed three substantial pharmaceutical partnering deals within 12 months and significantly expanded its investor base. Tim also has extensive listed company experience, including with pharmaceutical development company, Starpharma, where he worked to steer it through the IPO process and establishing several commercial relationships globally. Most recently, Tim has been consulting to companies in the health and medical technology sectors in Australia, providing strategic, government and regulatory advice. Tim holds a Bachelor of Law and a Bachelor of Science, majoring in chemistry, from the University of Melbourne.
Board Change • Jul 10No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 7 non-independent directors. Director Alex Huong was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.
New Risk • Jun 23New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.3m (US$9.58m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 4.6% per year over the past 5 years. Revenue is less than US$1m (AU$97k revenue, or US$65k). Market cap is less than US$10m (AU$14.3m market cap, or US$9.58m).
Board Change • Jun 22No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 7 non-independent directors. Director Alex Huong was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.
お知らせ • May 12Bio-Gene Technology Limited Announces Changes to the BoardBio-Gene Technology Limited announced the following changes to the Board and management: Due to significantly increased commitments associated with his other roles, Mr. Robert Klupacs has advised the Board that he will be retiring from the Board effective 31 July 2023. Before that time he will continue to act as Chair of the Company, and will be heavily involved in strategic negotiations for the company alongside the Bio- Gene management team. Robert joined Bio-Gene in 2015 as CEO and lead the Company to IPO in 2017, before becoming a Non-Executive Director in January 2018. Robert became Chair of the Company in November 2019. The Company also announces that Mr. Alex Ding and Mr. Chris Ramsay will join the Bio-Gene Board, effective immediately. Alex Ding was a partner at two leading Australian law firms, and is a recognised expert in mergers and acquisitions, capital markets, and general corporate and governance law. He has advised many large ASX, LSE and US listed companies, foreign government controlled entities and substantial private companies and funds on acquisitions, divestments, corporate finance transactions, joint venture arrangements, restructurings, corporate governance and disputes strategy. He has been named on The Best Lawyers in Australia list. Christopher Ramsay has over 30 years experience in the agricultural sector across business development, marketing and broader agronomy. He has held leadership roles in BASF and Nufarm among others, operating in both technical and managerial roles. Chris brings with him significant experience across customer engagement and product marketing and has a history of partnership development and sourcing after having spent the earlier years of his career in technical agricultural roles. Chris currently acts as non-executive director of North West Phosphate, a phosphate exploration and production business and principal director of a boutique agribusiness consulting firm. Chris holds a BSc (Honours) in Rural Sciences and a GradDip in Agribusiness.
Board Change • Apr 26No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Mar 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 24First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.01 loss in 1H 2022)First half 2023 results: AU$0.012 loss per share (further deteriorated from AU$0.01 loss in 1H 2022). Net loss: AU$1.97m (loss widened 37% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.
Board Change • Jan 05No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Dec 10No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 18Full year 2022 earnings released: AU$0.019 loss per share (vs AU$0.017 loss in FY 2021)Full year 2022 results: AU$0.019 loss per share (down from AU$0.017 loss in FY 2021). Net loss: AU$2.91m (loss widened 22% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 1% per year.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Non-Executive Director Andrew Guthrie was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 22First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: AU$0.01 loss per share (vs AU$0.01 loss in 1H 2021). Net loss: AU$1.44m (loss widened 8.1% from 1H 2021). Revenue missed analyst estimates by 95%. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 28Full year 2021 earnings released: AU$0.017 loss per share (vs AU$0.016 loss in FY 2020)Full year 2021 results: Net loss: AU$2.40m (loss widened 24% from FY 2020).
Breakeven Date Change • Jul 27Forecast to breakeven in 2024The analyst covering Bio-Gene Technology expects the company to break even for the first time. New forecast suggests the company will make a profit of AU$1.50m in 2024. Average annual earnings growth of 78% is required to achieve expected profit on schedule.
Breakeven Date Change • Jul 03Forecast to breakeven in 2024The analyst covering Bio-Gene Technology expects the company to break even for the first time. New forecast suggests the company will make a profit of AU$1.50m in 2024. Average annual earnings growth of 78% is required to achieve expected profit on schedule.
Reported Earnings • Feb 19First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.009 loss in 1H 2020)First half 2021 results: Net loss: AU$1.33m (loss widened 25% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
